Tech Company Financing Transactions
CytomX Therapeutics Funding Round
CytomX Therapeutics closed a $30 million funding round on 9/23/2010. Investors included Third Rock Ventures and Roche Venture Fund.
Transaction Overview
Company Name
Announced On
9/23/2010
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Third Rock Ventures (Lead Investor) (Charles Homcy)
Proceeds Purpose
Proceeds from the financing will be used to advance the company's unique antibody platform, expand the team and move the company to the Bay Area by the end of 2010.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 400
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
CytomX (NASDAQ: CTMX) is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean McCarthy
Chief Scientific Officer
Michael Kavanaugh
Vice President
Alison Joly
VP - Human Resources
Danielle Olander
VP - Manufacturing
Sridhar Viswanathan
Browse more venture capital transactions:
Prev: 9/23/2010: Glaukos venture capital transaction
Next: 9/23/2010: Watermark Medical venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs